Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

303 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-14

Study Completion Date

2022-11-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double-blind, double-dummy, placebo-controlled Phase 1b study evaluating the safety and immunogenicity of the investigational Cam2020 M2SR H3N2 influenza vaccine delivered IN alone or concomitantly with inactivated influenza vaccine (IIV) delivered IM to a healthy adult population age 65 to 85 years at time of enrollment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

NCT02563093

Influenza

COMPLETED PHASE4

Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over

NCT00232947

Influenza

COMPLETED PHASE3

Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age

NCT06641180

Influenza

COMPLETED PHASE3

Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults

NCT04576702

Influenza Human

COMPLETED PHASE2

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

NCT01946438

Influenza

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, double-blind, double-dummy, placebo-controlled Phase 1b study evaluating the safety and immunogenicity of the investigational Cam2020 M2SR H3N2 influenza vaccine delivered IN alone or concomitantly with IIV delivered IM to a healthy adult population age 65 to 85 years at time of enrollment. Eligible subjects will be randomized concurrently in a 3:3:3:1 ratio to receive one administration of Cam2020 M2SR alone (Cohort 1, n=90), Cam2020 M2SR along with IIV (Cohort 2, n=90), IIV alone (Cohort 3, n=90), or placebo (Cohort 4, n=30).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza Vaccine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Subjects assigned randomly to one of four cohorts concurrently

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Syringes wrapped to obscure color of contents

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

M2SR only dose

Intranasal M2SR vaccine and intramuscular placebo dose

Group Type EXPERIMENTAL

Cam2020 M2SR H3N2 influenza vaccine

Intervention Type BIOLOGICAL

Administered intranasally on Day 1

IM Placebo

Intervention Type OTHER

Administered intramuscularly on Day 1

M2SR with IIV dose

Intranasal M2SR vaccine and intramuscular IIV dose

Group Type EXPERIMENTAL

Cam2020 M2SR H3N2 influenza vaccine

Intervention Type BIOLOGICAL

Administered intranasally on Day 1

Fluzone HD IIV

Intervention Type BIOLOGICAL

Administered intramuscularly on Day 1

IIV only dose

Intranasal placebo dose and intramuscular IIV dose

Group Type ACTIVE_COMPARATOR

Fluzone HD IIV

Intervention Type BIOLOGICAL

Administered intramuscularly on Day 1

IN Placebo

Intervention Type OTHER

Administered intranasally on Day 1

Placebo only dose

Intranasal placebo dose and intramuscular placebo dose

Group Type PLACEBO_COMPARATOR

IN Placebo

Intervention Type OTHER

Administered intranasally on Day 1

IM Placebo

Intervention Type OTHER

Administered intramuscularly on Day 1

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cam2020 M2SR H3N2 influenza vaccine

Administered intranasally on Day 1

Intervention Type BIOLOGICAL

Fluzone HD IIV

Administered intramuscularly on Day 1

Intervention Type BIOLOGICAL

IN Placebo

Administered intranasally on Day 1

Intervention Type OTHER

IM Placebo

Administered intramuscularly on Day 1

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects must be willing and able to provide written informed consent to participate; a legally authorized representative (LAR) may not be used.
2. Males and nonchildbearing potential females 65-85 years of age at the time of consent.
3. Subjects must be willing to adhere to the requirements of the study and willing and able to communicate with the Investigator and understand the requirements of the study.
4. Healthy adults and those with stable chronic conditions as determined by medical history, physical examination, vital signs, clinical safety laboratory examinations and clinical judgment of the Investigator to be eligible for study inclusion.

Exclusion Criteria

1. Any acute or chronic physical or mental health condition that would limit the subject's ability to complete the study, increase risk of study participation or participant, or may interfere with interpretation of study results as based on the assessment by the Investigator.
2. Abnormal screening hematology or chemistry value per the US FDA Guidance: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials
3. Currently receiving, or planned to receive during the study, any immunosuppressive therapy.
4. Had a flu-like illness, influenza treatment, or prophylactic influenza viral drug administered in the previous 6 months before investigational product administration.
5. History of receipt of any live virus vaccine within 56 days of study entry, licensed or investigational vaccine within 28 days of Visit 01 or investigational drug within the past 6 months. An exception is made for receipt of a Covid-19 vaccine whether licensed or under EUA as long as the final dose was given at least 28 days prior to Visit 01.
6. Planned receipt of licensed vaccine, other than the study-provided licensed influenza vaccine, during the 28 days following Visit 01 or another investigational vaccine or investigational drug during the study period.
7. Receipt of blood/plasma products or immunoglobulin within 6 months before administration of the investigational product or planned for during the period of study participation.

Minimum Eligible Age

65 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes